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Abstract
Chemokine (C-C motif) receptor 2 (CCR2)-signaling can mediate accumulation of microglia at sites affected by
neuroinflammation. CCR2 and its main ligand CCL2 (MCP-1) might also be involved in the altered metabolism of beta-
amyloid (Ab) underlying Alzheimer’s disease (AD). We therefore measured the levels of CCL2 and three other CCR2 ligands,
i.e. CCL11 (eotaxin), CCL13 (MCP-4) and CCL26 (eotaxin-3), in the cerebrospinal fluid (CSF) and plasma of 30 controls and 119
patients with mild cognitive impairment (MCI) at baseline. During clinical follow-up 52 MCI patients were clinically stable for
five years, 47 developed AD (i.e. cases with prodromal AD at baseline) and 20 developed other dementias. Only CSF CCL26
was statistically significantly elevated in patients with prodromal AD when compared to controls (p=0.002). However, in
patients with prodromal AD, the CCL2 levels in CSF at baseline correlated with a faster cognitive decline during follow-up
(rs=0.42, p=0.004). Furthermore, prodromal AD patients in the highest tertile of CSF CCL2 exhibited a significantly faster
cognitive decline (p,0.001) and developed AD dementia within a shorter time period (p,0.003) compared to those in the
lowest tertile. Finally, in the entire MCI cohort, CSF CCL2 could be combined with CSF Tau, P-tau and Ab42 to predict both
future conversion to AD and the rate of cognitive decline. If these results are corroborated in future studies, CCL2 in CSF
could be a candidate biomarker for prediction of future disease progression rate in prodromal AD. Moreover, CCR2-related
signaling pathways might be new therapeutic targets for therapies aiming at slowing down the disease progression rate of
AD.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly population. Preceding onset of dementia, patients
typically exhibit milder symptoms of cognitive decline, so called
mild cognitive impairment (MCI). However, MCI is a heteroge-
neous syndrome and does not exclusively comprise cases with
prodromal AD (i.e. individuals with AD who have not yet
developed dementia), but also patients with stable MCI or patients
affected by early stages of other types of dementia disorders than
AD [1].
AD is characterized by the accumulation of b-amyloid (Ab) and
tau into senile plaques and neurofibrillary tangles, respectively
[2,3]. There is evidence suggesting that intracerebral inflamma-
tion, including microgliosis, can play a significant role in the
development of AD [4]. Senile plaques are often surrounded by
clusters of reactive astrocytes and microglia [4,5]. Aggregated Ab
can activate glial cells, which then may clear Ab. However,
activated glia cells release inflammatory mediators in this process,
including chemokines, that might contribute to neuronal dysfunc-
tion and cell death [4,5,6]. The chemokine C-C motif ligand 2
(CCL2; also called monocyte chemotactic protein-1 (MCP-1)),
which is produced by neurons and glial cells, activates the CCR2-
receptor and can induce chemotaxis of monocytes and microglia,
contributing to pathological microgliosis [7,8]. Interestingly,
several studies have shown that CCL2-signalling can exacerbate
Ab pathology in animal models of AD [9,10]. For example,
Yamamoto and colleagues have demonstrated that transgenic AD
mice expressing mutant APP exhibit increased Ab pathology when
also overexpressing CCL2 [9].
Biochemical changes in the brain are often reflected in the
cerebrospinal fluid (CSF), because of the proximity of CSF to the
neuronal tissue [11]. The CSF biomarkers Ab42 and tau can be
used to predict future development of AD dementia in patients
with MCI [12,13,14]. However, to our knowledge there are no
fluid biomarkers that can be used to predict the rate of the future
cognitive decline in persons affected by prodromal AD. Markers
associated with increased disease progression rate would be
valuable tools both in the clinic and in future therapeutic studies
when assessing patients during the pre-dementia stages of AD [11].
In the current study, we characterized the role of CCR2-related
chemokines during the pre-dementia stages of AD. Especially we
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faster rate of cognitive decline in subjects affected by prodromal
AD. Our hypothesis was that concomitant inflammation in the
brain might exaggerate AD-associated pathology. The study
population consisted of 30 controls and 119 patients with MCI
at baseline. All patients were followed over five years and this long
clinical follow-up time allowed us to distinguish subjects with
prodromal AD from cognitively stable MCI cases, and subjects
affected by other forms of dementia. Furthermore, the rate of
cognitive decline in individual patients over time could be
determined. The levels of the CCR2-ligands CCL2 (MCP-1),
CCL11 (eotaxin), CCL13 (MCP-4) and CCL26 (eotaxin-3) were
assessed in plasma and CSF obtained at baseline when all
individuals were still non-demented.
Methods
The study population was recruited at the memory disorder
clinic, Ska ˚ne University Hospital, Malmo ¨, Sweden (demographic
data are given in Table 1). At baseline, 119 patients with MCI
underwent thorough standard examinations conducted by a
trained physician, including neurological, physical and psychiatric
examinations. Patients were diagnosed with MCI according to
criteria from Peterson et al. [1] including: 1) memory complaint,
preferably corroborated by an informant; 2) objective memory
impairment adjusted for age and education, as judged by the
physician; 3) preservation of general cognitive functioning, as
determined by the clinicians judgment based on a structured
interview with the patient and a MMSE score greater than or
equal to 24; 4) no or minimal impairment of daily life activities; 5)
not fulfilling the DSM-IIIR criteria of dementia. Patients with
other causes of cognitive impairment, including subdural hema-
toma, brain tumor, CNS infection, schizophrenia, major depres-
sive episode, and current alcohol abuse were not included. The
patients with MCI at baseline were followed clinically until they
developed a certain form of dementia or until they had been
cognitively stable for .4 years. The patients who during clinical
follow-up received a diagnosis of AD had to meet the DSM-IIIR
criteria of dementia [15] and the criteria of probable AD defined
by NINCDS-ADRDA [16]. After clinical follow-up (median 5
years, range 4–7 years), 52 individuals (44%) remained cognitively
stable, 47 patients (40%) developed AD and 20 (17%) developed
other forms of dementia.
The control population consisted of 30 healthy volunteers who
underwent lumbar puncture at baseline. Inclusion criteria were the
absence of cognitive complaints or symptoms and preservation of
general cognitive functioning according to cognitive test (e.g.
MMSE, ADAS-cog, clock drawing). Exclusion criteria were active
neurological or psychiatric diseases. However, other medical
conditions that did not affect cognition were permitted.
At baseline, CSF samples were obtained by lumbar puncture in
the L3/L4 or L4/L5 interspace. The samples were then
immediately frozen and stored at 280uC pending biochemical
analyses. At baseline, non-fasting venous blood for plasma analyses
was collected in tubes containing EDTA, which were then
centrifuged. Plasma samples were stored in polypropylene tubes
at 280uC until biochemical analysis. Both CSF and plasma
samples were collected between 9 and 11 am.
Ethics Statement
All patients gave informed consent to participate in the study.
The study was conducted according to the provisions of the
Helsinki Declaration and approved by the ethics committee of
Lund University, Sweden.
Assays of CCL2, CCL11, CCL13 and CCL26 chemokines
Levels of chemokines in CSF and plasma were assessed by use of
the Human chemokine 9-plex ultra sensitive assay based on the
MesoScale technology. The assay is a multiplex type of ELISA
technology that relies on electrochemiluminescence. The assays
were run according to the manufacturer’s protocol (Meso Scale
Discovery, USA; http://www.mesoscale.com). Briefly, specific
antibodies that coat a working electrode at the bottom of the
well capture the molecule of interest. A second antibody labelled
with a SULFO-TAG
TM binds the molecule of interest. The
SULFO-TAG
TM emits light upon electrochemical stimulation
when a current is applied between the counter electrode and the
working electrode, and is registered by a SECTORT
TM Imager.
Duplicate readings for each standard and sample were averaged
and calibration curves were prepared in the supplied assay diluents
with a range of 80,000 pg/ml to 0.61 pg/ml, dependent upon the
chemokine. Detection limits are defined as 2.56 the standard
Table 1. Demographic data of included subjects.
Patient characteristics Controls (n=30) Stable MCI (n=52) MCI-AD (n=47) MCI-other (n=20)
Age at baseline (years) 72686 4 69
a 7466
b 7269
b
Gender (Male/Female) 13/17 28/24 11/3
b 13/7
APOE e4 carrier (%) 23 48 81
a, b 30
MMSE at baseline (0–30 p) 29.361.0 27.361.8
a 26.761.4
a 27.061.6
a
Annual decrease in MMSE score 20.0160.33 20.2160.45 3.362.5
a,b 2.662.3
a,b
CSF Tau, pg/ml 283697 3356203 7926367
a,b 4976609
CSF P-tau, pg/ml 57613 63616 96629
a,b 61631
CSF Ab42, pg/ml 7336161 5556191
a 317698
a,b 5716179
a
Data are the mean (6 standard deviation) or number (%).Only P-values,0.01 are considered significant, because of correction for multiple comparisons (all groups were
compared to both controls and stable MCI).
aP,0.01 vs Controls.
bP,0.01 vs Stable MCI.
Abbreviations: Stable MCI, patients with MCI with stable cognitive functions during a follow-up period of 5.2 years; MCI-AD, patients with MCI who developed
Alzheimer’s disease during follow-up; MCI-other, patients with MCI who developed other types of dementia during follow-up; CSF, cerebrospinal fluid; APOE,
apolipoprotein E; MMSE, Mini-Mental State Examination.
doi:10.1371/journal.pone.0030525.t001
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DiscoveryH: CCL2/MCP-1, 3.3 pg/mL; CCL11/Eotaxin, 10 pg/
mL; CCL13/MCP-4, 19 pg/mL; CCL26/Eotaxin-3, 14 pg/mL.
The intraassay coefficients of variation (CV) ranges were as
follows: CCL2: 1.1–6.5%; CCL11: 2.7–3.9%; CCL13: 2.7–5.4%;
and CCL26: 1.6–4.9%.
Statistical analyses
The non-parametric Mann-Whitney U-test, with adjustment for
multiple comparisons (see Table 1 and Table 2), was used to
compare continuous baseline data between the diagnostic groups
at follow-up. Pearson’s x
2 test was used for dichotomous variables.
The non-parametric Spearman’s rank correlation was used for
correlation analyses. Multivariate linear regression models (enter)
were also used to study the associations between CSF CCL2 and
the rate of cognitive decline measured as either annual decrease in
MMSE score during follow-up or time until conversion to
dementia. The models were adjusted for potentially confounding
factors, including age, gender, MMSE total score, education level
[participation in post-compulsory school] and APOE-e4 carrier
status [carriers of zero or at least one APOE-e4 alleles].The
statistical analyses were accomplished with SPSS for Windows,
version 18.01.
Results
Subjects and baseline values of chemokine levels
The demographic data and baseline levels of chemokines in
CSF and plasma are given in Table 1 and 2. In the control group
there were no significant associations between the chemokine
levels in CSF or plasma and age, gender, APOE4 genotype, and
baseline MMSE score (data not shown). Only the levels of CCL26
in CSF differed significantly between controls and patients with
MCI who subsequently developed AD (p=0.002) (Table 2).
Association between CCL2 and cognitive deterioration
rate in prodromal AD
When analyzing subjects with MCI who subsequently devel-
oped AD (i.e. subjects with prodromal AD) we found that the
CCL2 levels in CSF obtained at baseline were significantly
associated with a higher annual decrease in MMSE score
(rs=0.42, p=0.004; Figure 1) and with a shorter time to
conversion to AD (rs=20.39, p=0.006). When using multivariate
linear regression models and simultaneously including CSF CCL2,
age, gender, MMSE total score, education level and APOE-e4
carrier status, we found that only CSF CCL2 was significantly
associated with a higher annual decrease in MMSE score during
follow-up (p=0.009) or with a shorter time to conversion to AD
(p=0.016) (Table 3). Thus, higher CSF CCL2 levels are associated
with a faster rate of cognitive decline and with a shorter time to
conversion to dementia independent of potential confounding
factors. Moreover, the annual decrease in MMSE score was higher
in cases with prodromal AD who had baseline CSF CCL2 levels in
the highest tertile when compared to those in the lowest tertile
(Figure 2, p,0.001). Similarly, the time to conversion to dementia
was shorter in MCI-AD (i.e. prodromal AD) cases who had CCL2
levels in the highest tertile when compared to those in the lowest
tertile (Figure 2, p,0.003). However, there were no correlations
between CCL2 levels in plasma and annual decrease in MMSE and
with time to conversion to AD (p.0.05). CCL11, CCL13 and
CCL26 levels in plasma or CSF did not correlate with the
measures of disease progression rate (p.0.05).
Association between CCL2 and cognitive deterioration
rate in the whole MCI cohort
The underlying pathology in each individual seeking medical
advice due to MCI is not known until extensive clinical follow-up
or neuropathology has been performed. However, many studies
have shown that CSF Tau, P-tau and Ab42 can be used to identify
Table 2. The levels of chemokines in cerebrospinal fluid (CSF)
and plasma obtained at baseline.
CSF
Controls
n=30
Stable MCI
n=52
MCI-AD
n=47
MCI-other
n=20
CCL2 6496182 6766183 6846194 7296176
CCL11 11641 2 641 2 651 2 65
CCL13 14610 12610 16613 20629
CCL26 14619 33655 33648
a 16620
Plasma n=30 n=49 n=42 n=17
CCL2 149647 164644 1976277 172628
CCL11 4116193 4396193 3576288
b 4516159
CCL13 271698 3076108 2706160 3396154
CCL26 41645 656156 51662 30633
The chemokine levels are given in pg/ml. Only P-values,0.01 are considered
significant, because of correction for multiple comparisons (all groups were
compared to both controls and stable MCI).
aP,0.01 vs Controls.
bP,0.01 vs Stable MCI.
Abbreviations: Stable MCI, patients with MCI with stable cognitive functions
during a follow-up period of 5.2 years; MCI-AD, patients with MCI who
developed Alzheimer’s disease during follow-up; MCI-other, patients with MCI
who developed other types of dementia during follow-up; CSF, cerebrospinal
fluid.
doi:10.1371/journal.pone.0030525.t002
Figure 1. The baseline levels of CCL2 in the cerebrospinal fluid
correlated positively with the annual change in MMSE score
during clinical follow-up (rs=0.42, p=0.004).
doi:10.1371/journal.pone.0030525.g001
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dementia in the future. We therefore investigated whether CCL2
could be used in combination with these standard CSF biomarkers
to predict future cognitive decline in the whole MCI cohort. An
AD-indicative (pathological) CSF biomarker pattern was defined
as Tau.350 pg/ml and Ab42/P-tau ratio ,6.5 as previously
described [1]. As shown in Figure 3, patients with MCI who had a
normal (i.e. non AD-indicative) CSF biomarker pattern did not
decline cognitively over time as a group. In contrast, those with an
AD-indicative (pathological) CSF biomarker pattern worsened
cognitively over time, because many subjects in this group
developed AD dementia during follow-up. Importantly, the
subgroup with both an AD-indicative (pathological) CSF bio-
marker pattern and higher CCL2 levels in CSF at baseline
exhibited a significantly faster cognitive decline during follow-up
than the other subgroups (Figure 3).
Discussion
In the present study, we show that higher baseline CCL2 levels
in CSF were associated with a faster cognitive decline in patients
with MCI who subsequently developed AD. The results indicate
that elevated CCL2 levels in the brain might exacerbate the
ongoing neurodegeneration in subjects affected by prodromal AD.
Interestingly, overexpression of CCL2 levels in the brain of a
transgenic animal model of AD expressing mutant APP resulted in
a five-fold increase in Ab deposition [9]. Similarly, in another
study CCL2 caused increased microglial accumulation, Ab
oligomerization and cognitive decline in transgenic AD mice
[10]. In humans, CCL2 levels are increased in the CSF and brains
of demented individuals affected by AD and CCL2 co-localizes
with senile plaques [7,17]. Consequently, CCL2 associated
inflammation and microgliosis might have detrimental effects in
individuals with altered Ab metabolism. As a matter of fact, drugs
that modify CCL2/CCR2-signaling have already been developed
[18] and might be considered for therapeutic trials in prodromal
AD.
In the present study, the patients with prodromal AD do not
as a group have higher levels of CCL2 when compared to
cognitively stable MCI patients or controls. Therefore, CCL2-
associated brain inflammation and microgliosis seem to be
independent processes, not directly caused by early AD.
However, AD-related pathology might anyway be exaggerated
when it occurs simultaneously as brain inflammation in the
same individual. Recent evidence indicates that many elderly
individuals, without dementia or neurological disorders, exhibit
increased microglial activation and increased levels of inflam-
matory markers [19,20]. Thus, a variable degree of chronic
inflammation is often observed in the aged brain. We suggest
that the fluctuations in CCL2-levels found amongst the patients
with MCI reflect this low-grade immunological activity. It is
interesting to note that both epidemiological studies and animal
Figure 2. The disease progression rate is increased in cases
with prodromal AD who have higher levels of CCL2 in the
cerebrospinal fluid at baseline. Panel A shows that prodromal AD
cases in the highest tertile of CSF CCL2 at baseline exhibited a
significantly higher annual decrease in MMSE score during the follow-
up period compared to those in the lowest tertile (p,0.001, Mann
Whitney U test). Panel B depicts that prodromal AD cases in the highest
tertile of baseline CSF CCL2 exhibited a shorter time period to
conversion to dementia compared to those in the lowest tertile
(p,0.003, Mann Whitney U test). The CCL2 tertiles were established in
the whole MCI cohort (first tertile=292–584 pg/ml; second terile=585–
756 pg/ml; third tertile=757–1369 pg/ml). Error bars indicate the
standard error of the mean.
doi:10.1371/journal.pone.0030525.g002
Table 3. Multiple linear regression models for the association
between annual change in MMSE score during follow-up and
baseline levels of CSF CCL2, including potential confounding
factors.
Model 1 Model 2 Model 3
CCL2 in CSF 0.37 (2.67)* 0.37 (2.64)* 0.39 (2.70)**
Age at baseline 0.02 (0.11) 20.01 (20.08)
Gender 0.07 (0.46)
APOE e4 carrier 0.22 (1.53)
MMSE baseline 0.10 (0.72)
Higher education 20.12 (20.76)
R
2 0.14 0.14 0.20
Values are given as standardized beta coefficients (t-values).
*P,0.05;
**P,0.01.
doi:10.1371/journal.pone.0030525.t003
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related to AD), accompanied by elevated chemokine levels,
can lead to a significantly accelerated AD progression
[21,22,23]. It has therefore been suggested that cerebral
inflammation, resulting from normal aging or due to inflam-
matory events, might act in synergy with amyloid beta
pathology in cases affected by AD, leading to a steeper
cognitive decline [24]. According to the present results,
individuals with higher CCL2 levels, reflecting increased brain
inflammation, might be more susceptible to AD-pathology than
patients with lower levels of inflammatory markers. Further-
more, it is interesting to note in the present study that only
CCL2 levels in the CSF, and not in plasma, are associated with
an increased progression rate in prodromal AD, indicating that
the inflammatory processes important for the disease progres-
sion in AD are primarily localized in the brain.
The currently used fluid biomarkers for AD, i.e. CSF Ab42 and
CSF tau, are diagnostic markers that like amyloid PET images
change during the presymptomatic stages of the disease. These
markers are then quite stable over time [11], and they are not able
to predict the future rate of cognitive decline in prodromal AD
[12]. Accordingly, CSF Ab42 and CSF tau should primarily be
used as diagnostic markers detecting underlying disease state.
Other methods are needed to reflect the stage of the disease and
the rate of cognitive decline [11] and the present study suggest that
CSF CCL2 is a candidate biomarker for future disease progression
rate in prodromal AD.
Conclusions
Elevated CCL2-signaling in the brain might exacerbate the
progression rate of AD-related pathology during pre-dementia
stages. Consequently, CCL2-related signaling pathways might be
new targets for disease-modifying therapies aiming at slowing
down the disease process in patients with prodromal AD. If our
results are corroborated by other studies, CSF CCL2 could be
used when predicting the future rate of cognitive decline in
patients with prodromal AD.
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